Literature DB >> 15234300

Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis.

Dhananjay Shukla1, Jatinder Singh, Chandra Mohan Kolluru, Ramasamy Kim, Perumalsamy Namperumalsamy.   

Abstract

PURPOSE: To evaluate the efficacy and safety of transpupillary thermotherapy (TTT) for subfoveal neovascularization (SRNVM) in patients with group 2A Idiopathic Juxtafoveolar Telangiectasis (IJFT).
DESIGN: Nonrandomized interventional case series.
METHODS: We performed TTT for subfoveal SRNVM in 14 eyes of 13 patients with group 2A IJFT, who were referred to our tertiary care center. We evaluated visual outcome and SRNVM closure rate in these patients.
RESULTS: After a mean follow-up period of 8.65 months, 92.3% of treated eyes had stabilization or improvement in visual acuity as well as regression of SRNVM by fluorescein angiography (FA). One SRNVM showed persistent leakage. One patient worsened by more than 2 Snellen lines; one required retreatment.
CONCLUSION: Transpupillary thermotherapy may be a safe and useful alternative treatment option for patients with group 2A IJFT with subfoveal SRNVM.

Entities:  

Mesh:

Year:  2004        PMID: 15234300     DOI: 10.1016/j.ajo.2004.01.047

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

1.  Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia.

Authors:  Teresa Barth; Florian Zeman; Horst Helbig; Maria-Andreea Gamulescu
Journal:  Int Ophthalmol       Date:  2017-01-21       Impact factor: 2.031

2.  Subretinal neovascular membrane associated with type 2a idiopathic juxtafoveolar telangiectasis in pseudoxanthoma elasticum.

Authors:  Maurizio Battaglia Parodi; Pierluigi Iacono; Giuseppe Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-19       Impact factor: 3.117

3.  Relationship between intensity of reflected light and temperature increase: assessment of fundus pigmentation for transpupillary thermotherapy.

Authors:  Ryo Obata; Yasuhiro Tamaki; Yasuo Yanagi; Junko Kami
Journal:  Jpn J Ophthalmol       Date:  2007-12-21       Impact factor: 2.447

4.  One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia.

Authors:  Nazimul Hussain; Taraprasad Das; Rohit Khanna; L S Mohan Ram; Kallukuri Sumasri
Journal:  Clin Ophthalmol       Date:  2007-12

5.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 6.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

7.  Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia.

Authors:  Tuğba Aydoğan; Gürkan Erdoğan; Cihan Ünlü; Ahmet Ergin
Journal:  Turk J Ophthalmol       Date:  2016-12-01

Review 8.  Macular Telangiectasia Type 2: A Comprehensive Review.

Authors:  Kiran Chandra Kedarisetti; Raja Narayanan; Michael W Stewart; Nikitha Reddy Gurram; Arshad M Khanani
Journal:  Clin Ophthalmol       Date:  2022-10-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.